FDA approves Tecentriq in combination with Cotellic and Zelboraf for patients with advanced skin cancer

01/12/2021 By Dr. Dan Platt

Summary: The Food and Drug Administration (FDA) announced the approval of a new combination of three different drugs for the treatment of patients with BRAF V600 mutation-positive advanced melanoma. The new regimen combines an immunotherapy, Tecentriq (atezolizumab), with two targeted therapies, Cotellic (cobimetinib) and Zelboraf (vemurafenib).

Dr. Dan’s Takeaway: Adding Tecentriq to the combination of two approved targeted therapies extended survival from 10.6 months to 15.1 months in patients with advanced melanoma with a BRAF mutation. This is the first approval of these three types of drugs used in combination, but others will soon follow.



Deskside with Dr. Dan

“One small way I am personally contributing to education is through sharing my take on academic and industry articles, using my medical background to boil down the jargon and pull out the benefits of the news for you.”

– Dan Platt, M.D.

Chief Medical Officer

About The Poster

Leave a Reply

Your email address will not be published. Required fields are marked *

Explore the latest Hub posts


Top Tips for Dealing with Holiday Blues

Many people deal with the holiday blues, including several of our team members! The Gryt Health team came together to create this piece with some of our favorite tips and tricks for dealing with the Holiday Blues!

Tell Your Story

Irene’s Stomach Cancer Story

Gryt Health Community Member, Irene shares the start of her journey with Stomach Cancer.

Want Email Updates?

Get updates in your inbox when new content is posted on the website.

Find value in this post? Please share!

You are never alone

View our resources for those who are experiencing, have experienced, or are supporting someone who has experienced a medical diagnosis.